Pharmacological targets in gastro-oesophageal reflux disease

Basic and Clinical Pharmacology and Toxicology

Volumn 97, Issue 6, 2005, Pages 333-341

  Piche, Thierry ^a   Galmiche, Jean Paul ^b,c  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2,3 DIHYDRO 1 (2' METHYLPHENACYL) 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 2 OXO 1 PIVALOYLMETHYL 5 (2 PYRIDYL) 1H 1,4 BENZODIAZEPIN 3 YL] 3 [3 (METHYLAMINO)PHENYL]UREA; 8 BENZYLOXY 2 METHYLIMIDAZO[1,2 A]PYRIDINE 3 ACETONITRILE; ADENOSINE TRIPHOSPHATASE INHIBITOR; AZD 0865; BACLOFEN; BENATOPRAZOLE; BP2 94; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CS 526; ESOMEPRAZOLE; GASTRIN ANTAGONIST; HISTAMINE DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; ILAPRAZOLE; ITRIGLUMIDE; LANSOPRAZOLE; MOTILIN; POTASSIUM COMPETITIVE ADENOSINE TRIPHOSPHATASE BLOCKER; PROKINETIC AGENT; PROTON PUMP INHIBITOR; R 105266; REVAPRAZAN; S 0509; SORAPRAZAN; SPIROGLUMIDE; THIOPERAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; Z 360;

ACID SECRETION; AREA UNDER THE CURVE; CLINICAL TRIAL; DROWSINESS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG WITHDRAWAL; ESOPHAGUS MOTILITY; GASTROESOPHAGEAL REFLUX; HUMAN; LOWER ESOPHAGUS SPHINCTER; MUSCLE RELAXATION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RELAPSE; SEIZURE; SHORT SURVEY; STOMACH ACID SECRETION; STOMACH ACID SUPPRESSION; TRANSIENT LOWER ESOPHAGUS SPHINCTER RELAXATION;

ANIMALS; CHOLECYSTOKININ; CHOLINERGIC ANTAGONISTS; ESOPHAGEAL SPHINCTER, LOWER; GABA AGONISTS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; H(+)-K(+)-EXCHANGING ATPASE; HISTAMINE AGONISTS; HUMANS; MORPHINE; MUSCLE RELAXATION; NITRIC OXIDE SYNTHASE; PROTON PUMPS; RECEPTOR, CHOLECYSTOKININ B;

EID: 29744453300     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2005.pto_273.x     Document Type: Short Survey

References (79)

1. Adachi, K., Y. Komazawa, H. Fujishiro, T. Mihara, M. Ono, M. Yuki, A. Kawamura, M. A. Karim Rumi, Y. Amano & Y. Kinoshita: Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens. J Gastroenterol. 2003, 38, 915-917.
2. Allocca, M., M. Mangano, P. Colombo & R. Penagini: Effect of loperamide on gastro-oesophageal reflux. Scand. J. Gastroenterol. 2003, 38, 343-346.
3. Andersson, K., A. Aurell Holmberg, C. Briving & B. Holstein: Preclinical profile of AZD0865, a novel, selective, potassium-competitive acid blocker. Gastroenterology 2004, 126, A56.
4. Andersson, T.: Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin. Pharmacokinet. 1996, 31, 9-28.
5. Asano, S., A. Yoshida, H. Yashiro, Y. Kobayashi, A. Morisato, H. Ogawa, N. Takeguchi & M. Morii: The cavity structure for docking the K(+)-competitive inhibitors in the gastric proton pump. J. Biol. Chem. 2004, 279, 13968-13975.
6. Bado, A., J. P. Laigneau, L. Moizo, Y. Cherifi & M. J. Lewin: H3-receptor activation inhibits cholinergic stimulation of acid secretion in isolated rabbit fundic glands. J. Pharmacol. Exp. Therap. 1995, 275, 1099-1103.
7. Beltinger, J., P. Hildebrand, J. Drewe, A. Christ, K. Hlobil, M. Ritz, M. D'Amato, L. Rovati & C. Beglinger: Effects of spiroglumide, a gastrin receptor antagonist, on acid secretion in humans. Eur. J. Clin. Invest. 1999, 29, 153-159.
8. Blackshaw, L. A., E. Staunton, A. Lehmann & J. Dent: Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Amer. J. Physiol 1999, 277, G867-G874.
9. Boeckxstaens, G. E., D. P. Hirsch, N. Fakhry, R. H. Holloway, M. D'Amato & G. N. Tytgat: Involvement of cholecystokinin A receptors in transient lower esophageal sphincter relaxations triggered by gastric distension. Amer. J. Gastroenterol 1998, 93, 1823-1828.
10. Boulant, J., J. Fioramonti, M. Dapoigny, G. Bommelaer & L. Bueno: Cholecystokinin and nitric oxyde in transient lower esophageal sphincter relaxation to gastric distension in dogs. Gastroenterology 1994, 107, 1059-1066.
11. Boulant, J., S. Mathieu, M. D'Amato, A. Abergel, M. Dapoigny & G. Bommelaer: Cholecystokinin in transient lower oesophageal sphincter relaxation due to gastric distension in humans. Gut 1997, 40, 575-581.
12. Champion, G., J. E. Richter, S. Singh, C. Schan & H. Nellans: Effect of oral erythromycin on esophageal pH and pressure profiles in patients with gastroesophageal reflux disease. Dig. Dis. Sci. 1994, 39, 129-137.
13. Chiba, N., C. J. De Cara, J. M. Wilkinson & R. H. Hunt: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997, 112, 1798-1810.
14. Christofides, N. D., R. G. Long, M. L. Fitzpatrick, G. P. McGregor & S. R. Bloom: Effect of motilin on the gastric emptying of glucose and fat in humans. Gastroenterology 1981, 80, 456-460.
15. Ciccaglione, A. F. & L. Marzio: Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003, 52, 464-470.
16. Clave, P., A. Gonzales, A. Moreno, R. Lopez, A. Farre, X. Cusso, M. D'Amato, F. Azpiroz & F. Lluis: Endogenous cholecystokinin enhances postprandial gastroesophageal reflux in humans through extrasphincteric receptors. Gastroenterology 1998, 115, 597-604.
17. Corruzzi, G., M. Adami & G. Bertaccini: Histamine H3 receptors are not involved in the regulation of rat gastric secretion. Pharmacology 1992, 44, 190-195.
18. Corruzzi, G., G. Morini, M. Zadami & D. Grandi: Role of histamine H3 receptors in the regulation of gastric functions. J. Physiol Pharmacol. 2001, 52, 539-553.
19. Crawley, J. A. & C. M. Schmitt: How satisfied are chronic heartburn sufferers with their prescription medications ? Results of the patient unmet needs survey. J. Clin. Outcomes Management 2000, 7, 29-34.
20. Degen, L., D. Matzinger, M. Merz, S. Appel-Dingemanse, S. Osborne, S. Luchinger, R. Bertold, H. Maecke & C. Beglinger: Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment. Pharmacol. Therap. 2001, 15, 1745-1751.
21. Fang, J. C., I. Sarosiek, Y. Yamamoto, J. Liu & R. K. Mittal: Cholinergic blockade inhibits gastro-oesophageal reflux and transient lower oesophageal sphincter relaxation through a central mechanism. Gut 1999, 44, 603-607.
22. Finizia, C., L. Lundell, L. Cange & M. Ruth: The effect of cisapride on oesophageal motility and lower esophageal sphincter function in patients with gastro-oesophageal reflux disease. Eur. J. Gastroenterol. Hepatol. 2002, 14, 9-14.
23. Galmiche, J. P., S. Bruley des Varannes, P. Ducrotté, S. Sacher-Huvelin, F. Vavasseur, A. Taccoen, P. Fiorentini & M. Homerin: Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life. Effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment. Pharmacol. Therap. 2004, 19, 655-662.
24. Galmiche, J. P., S. Sacher-Huvelin, S. Bruley des Varannes, F. Vavasseur, A. Taccoen, P. Fiorentini & M. Homerin: A comparative study of the early effects of tenatoprazole and esomeprazole 40 mg on intragastric pH in healthy volunteers. Aliment. Pharmacol Therap. 2005, 21, 575-582.
25. Graul, A., N. Mealy & M. Bayes: Annual update 2003: gastrointestinal drugs. Drugs of the Future 2003, 28, 797-840.
26. Han, K. S., Y. G. Kim, J. K. Yoo & M. G. Lee: Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats. Biopharm. Drug. Dispos. 1998, 19, 493-500.
27. Hirsch, D. P., R. H. Holloway, G. N. Tytgat & G. E. Boeckxstaens: Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology 1998, 115, 1374-1380.
28. Hirsch, D. P., N. M. Tiel-Van Buul, G. N. Tytgat & G. E. Boeckxtaens: Effect of L-NMMA on postprandial transient lower esophageal sphincter relaxations in healthy volunteers. Dig. Dis. Sci. 2000, 45, 2069-2075.
29. Hirsch, D. P., G. N. Tytgat & G. E. Boeckxstaens: Is glutamate involved in transient lower esophageal sphincter relaxations? Dig. Dis. Sci. 2002, 47, 661-666.
30. Holloway, R. H.: Treatment of gastro-oesophageal reflux disease through control of transient lower oesophageal sphincter relaxations-feasibility, practicality and possibilities. Digest. Liver. Dis. 2000, 32, 183-187.
31. Hunt, R. H., D. Armstrong, C. James, S. K. Chowdhury, Y. Yuan, P. Fiorentini, A. Taccoen & P. Cohen: Effect of intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Amer. J. Gastroenterol. 2005, 100, 1-8.
32. Kahrilas, P. J., E. M. M. Quigley, D. O. Castell & S. Spechler: The effect of tegaserod (HT 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment. Pharmacol. Therap. 2000, 14, 1503-1509.
33. Kil, B. J., I. W. Kim, C. Y. Shin, J. H. Jeong, C. H. Jun, S. M. Lee, D. Y. Kim, I. H. Huh & U. D. Sohn: Comparison of IY81149 with omeprazole in rat reflux oesophagitis. J. Auton. Pharmacol. 2000, 20, 291-296.
34. B agonist baclofen in patients with symptoms and duodeno-gastro- oesophageal reflux refractory to proton pump inhibitors. Gut 2003, 52, 1397-1402.
35. Koerselman, J., K. G. Pursani, P. Peghini, M. A. Mohiuddin, D. Katzka, L. M. Akkermans & D. O. Castell: Different effects of an oral anticholinergic drug on gastroesophageal reflux in upright and supine position in normal, ambulant subjects: a pilot study. Amer. J. Gastroenterol. 1999, 94, 925-930.
36. Konturek, J. W., P. Thor, A. Lukaszyk, A. Gabryelewicz, S. J. Konturek & W. Domschke: Endogenous nitric oxide in the control of esophageal motility in humans. J. Physiol. Pharmacol. 1997, 48, 201-209.
37. Kwon, D., J. B. Chae, C. W. Park, Y. S. Kim, S. M. Lee, E. J. Kim, I. H. Huh, D. Y. Kim & K. D. Cho: Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo. Arzneimittelforsch. 2001, 51, 204-213.
38. Lehmann, A. & L. Brändén: Effects of antagonism of NMDA receptors on transient lower esophageal sphincter relaxations in the dog. Eur. J. Pharmacol. 2001, 431, 253-258.
39. B receptor inhibits transient lower esophageal sphincter relaxation in dogs. Gastroenterology 1999, 117, 1147-1154.
40. Lehmann, A., L. A. Blackshaw, L. Brändén, A. Carlsson, J. Jensen, E. Nygren & S. D. Smid: Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 2002, 123, 1129-1134.
41. Lidums, I., H. Bermingham & R. H. Holloway: Effect of hyoscine butylbromide on gastroesophageal reflux and lower esophageal sphincter in healthy subjects. Gastroenterology 1997, 112, A778.
42. Lidums, I., H. Checklin, R. K. Mittal & R. H. Holloway: Effect of atropine on gastro-oesophageal reflux and transient lower oesophageal sphincter relaxations in patients with gastro-oesophageal reflux disease. Gut 1998, 43, 12-16.
43. Lidums, I., A. Lehmann, H. Checklin, J. Dent & R. H. Holloway: Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000, 118, 7-13.
44. Mittal, R. K., C. Chiareli, J. Liu, R. H. Holloway & W. Dixon: Atropine inhibits gastric distension and pharyngeal receptor mediated lower oesophageal sphincter relaxation. Gut 1997, 41, 285-290.
45. Nariwasa, T., N. E. Magadia, J. H. Weisburger & E. L. Wynder: Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of N-methyl-N′-nitro-Nnitrosoguanidine in rats. J. Natl. Cancer Inst. 1974, 53, 1093-1097.
46. Netzer, P., B. Schmitt & W. Inauen: Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol. Therap. 2002, 16, 1481-1490.
47. Nishida, A., Y. Takinami, H. Yuki, A. Kobayashi, S. Akuzawa, T. Kamato, H. Ito, M. Yamano, Y. Nagakura & K. Miyata: YM022 [(R)-1-[2,3-dihydro-1- (2′- methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- 3(3methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. J Pharmacol. Exp. Therap. 1994, 270, 1256-1261.
48. Oh, T. Y., J. S. Lee, B. O. Ahn, H. Cho, W. B. Kim, Y. J. Surh, S. W. Cho, K. M. Lee & K. B. Hahm: Oxidative stress is more important than acid in the pathogenesis of reflux oesophagitis in rats. Gut 2001, 49, 364-371.
49. Park, S., S. Lee, K. Song, B. Lee & J. Kang: The pharmacological properties of a novel acid pump antagonist, YH1885. Gut 2003, 52, A9.
50. Penagini, R. & P. A. Bianchi: Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation. Gastroenterology 1997, 113, 409-414.
51. Pendley, C. E., L. R. Fitzpatrick, A. J. Capolino, M. A. Davis, N. J. Esterline, A. Jakubowska, P. Bertrand, C. Guyon, M.C. Dubroeucq & C. E. Martin: A gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Therap. 1995, 273, 1015-1022.
52. Robinson, M.: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders. Aliment. Pharmacol. Therap. 2004, 20, 30-37 (review).
53. Rouzade, M. L., J. Fioramonti & L. Bueno: Rôle des récepteurs 5-HT3 dans le contrôle par la cholécystokinine des relaxations transitoires du sphincter inférieur de l'œsophage chez le chien. Gastroenterol. Clin. Biol. 1996, 20, 575-580.
54. Sarna, S. K., A. Gonzales & R. P. Ryan: Enteric locus of action of prokinetics: ABT-229, motilin, and erythromycin. Amer. J. Physiol. Gastrointest. Liver. Physiol 2000, 278, G744-G752.
55. Sifrim, D., R. H. Holloway, J. Tack, A. Zelter, T. Missotten, B. Coulie & J. Janssens: Effect of sumatriptan, a 5HT1 agonist, on the frequency of transient lower esophageal sphincter relaxations and gastroesophageal reflux in healthy subjects. Amer. J. Gastroenterol. 1999, 94, 3158-3164.
56. Soldani, G., S. Bertini, A. Rouleau, J. Schwartz & G. Coruzzi: Gastric antisecretory effects of compound BP 2-94: a histamine H3-receptor agonist prodrug. Dig. Dis. Sci. 1999, 44, 2380-2385.
57. Soldani, G., M. Garbarg, L. Intorre, S. Bertini, A. Rouleau & J. C. Schwartz: Modulation of pentagastrin-induced histamine release by histamine H3 receptors in the dog. Scand. J. Gastroenterol. 1996, 31, 631-638.
58. Soldani, G., L. Intorre, S. Bertini, E. Luchetti, G. Coruzzi & G. Bertaccini: Regulation of gastric acid secretion by histamine H3 receptors in the dog: an investigation into the site of action. Naunyn-Schmiedebergs Arch. Pharmacol. 1994, 350, 218-223.
59. Stark, H., M. Krause, A. Rouleau, M. Garbarg, J. C. Schwartz & W. Schunack: Enzyme-catalyzed prodrug approaches for the histamine H3-receptor agonist (R)-alpha-methylhistamine. Bioorg. Med. Chem. 2001, 9, 191-198.
60. Steel, K.: Gastrin and gastrin receptor ligands - a review of recent patent literature. I. Drugs 2002, 5, 689-695.
61. Straathof, J. W., C. M. Lamers & A. A. Masclee: Effect of gastrin-17 on lower esophageal characteristics in man. Dig. Dis. Sci. 1997, 42, 2547-2551.
62. Straathof, J. W., S. Tieleman, C. M. Lamers & A. A. Masclee: Somatostatin prevents meal induced alterations in lower esophageal sphincter function. Gut 1996, 39, A183.
63. Strombeck, D., D. Griffin & D. Harrold: Eructation of gas through the gastroesophageal sphincter before and after limiting distension of the gastric cardia or infusion of a B-adrenergic amine in dogs. Amer. J. Vet. Res. 1989, 50, 751-753.
64. Takeuchi, K., T. Hirata, H. Yamamoto, T. Kunikata, M. Ishikawa & Y. Ishiara: Effects of S-0509, a novel CCKB/gastrin receptor antagonist, on acid secretion and experimental duodenal ulcers in rats. Aliment. Pharmacol. Therap. 1999, 13, 87-96.
65. Tomita, R., K. Tanjoh & K. Munakata: The role of motilin and cisapride in the enteric nervous system of the lower esophageal sphincter in humans. Surg. Today 1997, 27, 985-992.
66. Tottrup, A., D. Svane & A. Forman: Nitric oxide mediating NANC inhibition in opossum lower esophageal sphincter. Amer. J. Physiol. 1991, 260, G385-G389.
67. Tougas, G., Y. Chen, D. Luo, J. Salter, T. D' Elia & D. L. Earnest: Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms. Gastroenterology 2003, 124, A54.
68. Trudgill, N. J., F. N. Hussain, M. Moustafa, R. Ajjan, M. D'Amato & S. A. Riley: The effect of cholecystokinin antagonism on postprandial lower esophageal function in asymptomatic volunteers and patients with reflux disease. Aliment. Pharmacol. Therap. 2001, 15, 1357-1364.
69. Tytgat, G. N.: Shortcomings of the first-generation proton pump inhibitors. Eur. J. Gastroenterol. Hepatol. 2001, 13, S29-S33.
70. Van der Hijden, H. T., H. P. Koster, H. G. Swarts & J. J. De Pont: Phosphorylation of H+/K+-ATPase by inorganic phosphate. The role of K+ and SCH 28080. Biochim. Biophys. Acta 1991, 1061, 141-148.
71. Van Herwaarden, M. A., M. Samson, C. H. M. Van Nispen, M. Verinden & A. J. P. Smout: The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal function in patients with gastro-oesophageal reflux disease. Eur. J. Gastroenterol. Hepatol. 2000, 14, 453-462.
72. Vela, M. F., L. Camacho-Lobato & R. Srinivasan: Simultaneous intraesophageal impedance and pH measurement of acid and non acid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001, 120, 1599-1606.
73. Vela, M. E, R. Tutuian, P. O. Katz & D. O. Castell: Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment. Pharmacol. Therap. 2003, 17, 243-251.
74. Vigneri, S., M. Tonini, C. Scarpignato & V. Savarino: Improving opportunities for effective management of gastro-oesophageal reflux disease. Digest. Liver Dis. 2001, 33, 719-729 (review).
75. Wetscher, G. J., R. A. Hinder, D. Bagchi, P. R. Hinder, M. Bagchi, G. Perdikis & T. McGinn: Reflux esophagitis in human is mediated by oxygen derived free radical. Amer. J. Gastroenterol. 1995, 170, 522-557.
76. Wurts, W. & M. Hartman: Current status of acid pump antagonists (reversible PPIs). Yale J. Biol. Med. 1996, 69, 233-243.
77. Yu, K. S., K. S. Bae, J. H. Shon, J. H. Cho, S. Y. Yi, J. Y. Chung, H. S. Lim, I. J. Jang, S. G. Shin, K. S. Song & B. S. Moon: Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J. Clin. Pharmacol. 2004, 44, 73-82.
78. Zerbib, E, S. Bruley Des Varannes, C. Scarpignato, V. Leray, M. D'Amato, C. Roze & J. P. Galmiche: Endogenous cholecystokinin in postprandial lower esophageal sphincter function and fundic tone in humans. Amer. J. Physiol. 1998, 275, G1266-G1273.
79. Zhang, Q., A. Lehmann, R. Rigda, J. Dent & R. H. Holloway: Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002, 50, 19-24.